TY - JOUR
T1 - Chronic diarrhea and juvenile cataracts
T2 - Think cerebrotendinous xanthomatosis and treat
AU - Berginer, Vladimir M.
AU - Gross, Bella
AU - Morad, Khayat
AU - Kfir, Nechama
AU - Morkos, Siman
AU - Aaref, Salameh
AU - Falik-Zaccai, Tzipora C.
PY - 2009/1
Y1 - 2009/1
N2 - Cerebrotendinous xanthomatosis is an autosomal recessive disease of bile acid synthesis caused by 27-hydroxylase deficiency. Treatment with chenodeoxycholic acid normalizes cholestanol concentrations and abrogates progression of the disease. We present 4 patients with cerebrotendinous xanthomatosis within 1 family who were treated with chenodeoxycholic acid for 14 years. Two young sisters started treatment at the preclinical stage before the appearance of major symptoms. Their 2 older uncles, who had already developed the complete phenotypic form of cerebroten-dinous xanthomatosis when diagnosed, commenced treatment at the same time as the sisters, thus establishing a natural control group. After 14 years of chenodeoxycholic acid therapy, the cholestanol levels of all 4 patients decreased to normal levels( < 6 μ g/mL). Both sisters remained asymptomatic. Only moderate improvement in symptoms was observed in their uncles. In this long-term study, prompt preclinical administration of chenodeoxy-cholic acid in early childhood completely prevented the cerebrotendinous xanthomatosis phenotype in 2 sisters. Pediatricians should be aware of this diagnostic possibility of cerebrotendinous xanthomatosis in children presenting with chronic diarrhea and juvenile cataracts. Prevention is particularly significant in light of the availability of early genetic diagnosis and the devastating effects of this illness if not treated.
AB - Cerebrotendinous xanthomatosis is an autosomal recessive disease of bile acid synthesis caused by 27-hydroxylase deficiency. Treatment with chenodeoxycholic acid normalizes cholestanol concentrations and abrogates progression of the disease. We present 4 patients with cerebrotendinous xanthomatosis within 1 family who were treated with chenodeoxycholic acid for 14 years. Two young sisters started treatment at the preclinical stage before the appearance of major symptoms. Their 2 older uncles, who had already developed the complete phenotypic form of cerebroten-dinous xanthomatosis when diagnosed, commenced treatment at the same time as the sisters, thus establishing a natural control group. After 14 years of chenodeoxycholic acid therapy, the cholestanol levels of all 4 patients decreased to normal levels( < 6 μ g/mL). Both sisters remained asymptomatic. Only moderate improvement in symptoms was observed in their uncles. In this long-term study, prompt preclinical administration of chenodeoxy-cholic acid in early childhood completely prevented the cerebrotendinous xanthomatosis phenotype in 2 sisters. Pediatricians should be aware of this diagnostic possibility of cerebrotendinous xanthomatosis in children presenting with chronic diarrhea and juvenile cataracts. Prevention is particularly significant in light of the availability of early genetic diagnosis and the devastating effects of this illness if not treated.
KW - CDCA
KW - CTX
KW - CYP27A1 gene
KW - Cerebrotendinous xanthomatosis
KW - Cholestanol, chenodeoxycholic acid
KW - Chronic diarrhea in infancy and childhood
KW - Juvenile cataracts
UR - http://www.scopus.com/inward/record.url?scp=59449087114&partnerID=8YFLogxK
U2 - 10.1542/peds.2008-0192
DO - 10.1542/peds.2008-0192
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 19117873
AN - SCOPUS:59449087114
SN - 0031-4005
VL - 123
SP - 143
EP - 147
JO - Pediatrics
JF - Pediatrics
IS - 1
ER -